Provided by Tiger Trade Technology Pte. Ltd.

Carpenter Technology

387.10
-4.0700-1.04%
Post-market: 387.100.00000.00%19:30 EDT
Volume:688.10K
Turnover:265.36M
Market Cap:19.18B
PE:36.80
High:391.02
Open:384.84
Low:379.94
Close:391.17
52wk High:625.99
52wk Low:233.78
Shares:49.56M
Float Shares:48.15M
Volume Ratio:0.95
T/O Rate:1.43%
Dividend:0.80
Dividend Rate:0.21%
EPS(TTM):10.52
EPS(LYR):10.52
ROE:25.75%
ROA:11.87%
PB:8.61
PE(LYR):36.80

Loading ...

JPMorgan ups Carpenter target, places on ‘Negative Catalyst Watch’

TIPRANKS
·
Jul 14

U.S. Research Roundup: Airbnb, Doordash, Zillow Group

Reuters
·
Jul 14

Billionaires are Loading up on These Superior Stocks. Why it Pays to Follow Their Money.

Dow Jones
·
Jul 14

J.P. Morgan Remains a Buy on Carpenter Technology (CRS)

TIPRANKS
·
Jul 13

Poolbeg Pharma Begins POLB 001 Trial, Targets Major CRS Market Opportunity

TIPRANKS
·
Jul 13

Is Carpenter Technology (CRS) Fully Valued Following Its Russell Index Removals?

Simply Wall St.
·
Jul 10

Carpenter Tech is Maintained at Positive by Susquehanna

Dow Jones
·
Jul 10

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

GlobeNewswire
·
Jul 07

Carpenter Technology Announces Conference Call and Webcast

GlobeNewswire
·
Jul 01

Carpenter Tech is Maintained at Overweight by Keybanc

Dow Jones
·
Jun 30

Analysts’ Top Industrial Goods Picks: Carpenter Technology (CRS), AeroVironment (AVAV)

TIPRANKS
·
Jun 30

Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development

GlobeNewswire
·
Jun 25

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewswire
·
Jun 14

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

GlobeNewswire
·
Jun 14

Movement Alert|Carpenter Technology Rises 5.01% in Regular Trading, Trading at $548.98

Market Focus
·
Jun 11

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

GlobeNewswire
·
Jun 11

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

GlobeNewswire
·
Jun 11

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

GlobeNewswire
·
Jun 11

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

GlobeNewswire
·
Jun 10

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

GlobeNewswire
·
Jun 09